Skip to main content
. 2022 May 30;25(6):104481. doi: 10.1016/j.isci.2022.104481

Figure 6.

Figure 6

Durable antitumor effect of ppM1 treatment depended on T cells

(A) The schedule of tumor therapy experiments in Figures 6B–6E, ppM1 treatment with or without CD8α antibody or CD4 antibody (200 μg/mouse) for three times for depleting CD8+ or CD4+ T cells on MC38-bearing C57BL/6 model (n = 6–8).

(B and C) Tumor volume (B) and overall survival curves (C) of the groups without CD8 or CD4 depletion.

(D and E) Tumor volume (D) and overall survival curves (E) of the groups with CD8 or CD4 depletion.

(F and G) Antitumor efficacy of ppM1 on MC38-nude mice model (n = 8), tumor volume (F), survival curves (G). All error bars represent SEMs. (B), (D), and (F) was analyzed with two-tailed unpaired t test; (C), (E), and (G) was analyzed with log rank (Mantel–Cox) test. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001 (See also Figure S9).